Wednesday, December 05, 2012

Global Growth for Stevia; WILD Flavors, Sunwin Stevia's (OTCQB:SUWN) Distribution Partner, Sees Results One year after the European Union Grants Approval

Point Roberts, WA - December 5, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research for independent investors issues a sector snapshot on the stevia market and stevia stocks including Sunwin Stevia International, Inc. (OTCQB: SUWN), following recent news of Health Canada's approval for stevia as an ingredient in food and beverages.

Recently President of the International Stevia Council (ISC) said Stevia had fundamentally changed the sweetener market. Lauren Bandy, Ingredients Research Analyst with Euromonitor International told Investorideas.com, "There is no doubt that stevia has shaken the high intensity sweeteners market, most of all because it is sourced naturally. This puts it at a great advantage to other high intensity sweeteners such as aspartame and sucralose, which are chemically derived. It still is relatively expensive compared to other sweeteners such as sugar, and only represents 2% of the high intensity sweeteners market in volume terms in 2012, although this has doubled since 2011."
She went on to note, "I think stevia manufacturers will continue to target large, multinational brands, as they are at the moment. Stevia offers food and beverage manufacturers a way to reduce the sugar content of their products in a more natural way. Health and wellness is a key trend in the food and beverage sector and stevia is perfectly positioned to capitalize on the growth of the better-for-you market."
According to Foodingredientsfirst.com, "One year after the European Union granted approval for steviolglycosides to be marketed, WILD Flavors ( Sunwin Stevia's (OTCQB:SUWN) distribution partner) has noted positive interim results. The great-taste expert has worked with customers to create a number of stevia-sweetened products that have been market successes — everything from beverages to candies."
Sunwin (OTCQB:SUWN) began an expansion production project in April 2012 in anticipation of an improvement in demand in the coming years as the use of stevia as a healthy low calorie sweetener continues to increase across the globe. Sunwin has begun trial production of its new lines and anticipates its added production capabilities to be fully operational in the first quarter of calendar 2013.
Investorideas.com Newswire Lauren Bandy reports " Western Europe is the world's largest packaged food market in value terms and was worth just under US$600 billion in 2012. Since its EU approval, stevia suppliers have really been tapping into this lucrative market. Euromonitor shows that stevia consumption in Western Europe in volume terms is forecast to grow by 50% over 2012-2016, from 190 tonnes in 2012 to nearly 300 tonnes in 2016.
A number of key brands have since launched stevia containing products in Europe - for example in France and Ireland, the Coca Cola Company has reformulated Sprite using stevia, reducing sugar content by 30%."
Health Canada just gave stevia the okay to become an ingredient in mainstream food and beverages. PureCircle Limited (LSE:PURE.L) one of the world's leading producer of high purity stevia ingredients for the global food and beverage industry and GLG Life Tech (GLGLF) say they have been ramping up for the anticipated Canadian approval according to a recent article in foodnavigator-usa.com.
In terms of potential obstacles Lauren Bandy said there are a few to overcome. " India is the most significant market and the last of the BRIC countries not to permit stevia as a sweetening ingredient. Countries in Latin America and Asia Pacific - which also have the fastest growing packaged food and soft drink markets globally - have been using stevia for many years.
The other hurdle to stevia's global success is the controversy surrounding its natural status, a debate which is stronger in Europe than America. Because stevia has an E number (E960) and because steviol glycosides - the sweet compounds - have to be extracted from the plant and processed, some consumers consider stevia as ‘just another additive'.
Stevia's bitter aftertaste also remains an obstacle, although this is a highly researched and rapidly developing area and is unlikely to affect its market penetration; Euromonitor forecast that stevia will have an annual growth rate of 23% globally over 2011-2016, in volume terms."
To address any concerns with taste, WILD's Sunwin Stevia™ (OTCQB:SUWN) brand provides beverage manufacturers one-source solutions: high-quality Stevia extracts in varying Reb Alevels plus WILD's natural Taste Optimization Technology.
The natural Taste Optimization Technology eliminates the characteristic licorice nuance and partly bitter aftertaste of Stevia. Manufacturers can therefore create delicious tasting, naturally sweetened products with the natural sweetening system Stevia, ranging from near waters, tea drinks or carbonated soft drinks, to fruit juice-containing drinks and beer mixes. WILD's Sunwin Stevia™ allows for great-tasting calorie-reduced, low calorie or calorie-free varieties, according to customer demands and market requirements.
About WILD Flavors GmbH,
WILD Flavors GmbH, based in Zug, Switzerland, is one of the world's leading privately-owned manufacturers of natural ingredients for the food and beverage industry. WILD Flavors provides specific flavors, colors, and ingredients as well as innovative and great tasting concepts through application expertise and technological advancements. www.wildflavors.com or www.wild.de
About Sunwin Stevia International, Inc. (OTCQB: SUWN)
Sunwin Stevia International, Inc. engages in the areas of zero calorie, all natural sweeteners (Sunwin Stevia™ Extracts). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. For more info about Sunwin, please visit http://www.sunwininternational.com
Contact:
SUWN contact: Dore Perler
U.S. Representative
954-232-5363
ir@sunwininternational.com
Lauren Bandy works as Ingredients Research Analyst with Euromonitor International. She directly contributes to the content and quality of Euromonitor International's Food & Drinks Ingredients research, with a special focus on health ingredients, sweeteners, and cocoa ingredients. Lauren monitors key industry trends and forecasts and is responsible for the writing of articles and analysis, which provide detailed insight into the state of the industry. In her current role at Euromonitor International, Lauren uses her expert knowledge of the ingredients industry to create quality data and insight on a range of topics including key market trends and opportunities, regulation and innovative ingredients.
Lauren holds a degree in Nutrition from King's College, London.
Investorideas.com Newswire Research more Agriculture and stevia stocks at Investorideas.com
http://www.investorideas.com/MSS/Arg_Stock_List.asp
Article source: http://www.foodingredientsfirst.com/news/Wild-Sees-Positive-Interim-Results-One-Year-After-Stevia-Approval.html
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
More Sunwin info at Investorideas.com http://www.investorideas.com/CO/SUWN/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com is compensated by China Direct on behalf of SUWN, averaging four thousand two hundred per week for news publication, dissemination and profile on Invesotrideas.com , its affiliate news and email sites including ir app on Running Bull http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Mining Stock News: SilverCrest (TSX.V: SVL) (NYSE MKT: SVLC) Announces Grant of Stock Options

VANCOUVER, BRITISH COLUMBIA - December 5, 2012 (Investorideas.com Mining Stocks Newswire) SilverCrest Mines Inc. (TSX.V:SVL) ( NYSE MKT: SVLC) (CW5.F) (the "Company") announces the grant of stock options to directors, officers, employees and consultants to purchase an aggregate of 1,760,000 common shares of the Company at an exercise price of $2.60 per share for a term of 5 years. One quarter of these options vest on the date of grant and a further one-quarter will vest every six months thereafter.

SilverCrest Mines Inc. (TSX-V: SVL; NYSE MKT: SVLC) is a Canadian precious metals producer headquartered in Vancouver, BC. SilverCrest's flagship property is the 100%-owned Santa Elena Mine, located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, Mexico. The mine is a high-grade, epithermal gold and silver producer, with an estimated life of mine cash cost of US$8 per ounce of silver equivalent (55:1 Ag:Au). SilverCrest anticipates that the 2,500 tonnes per day facility should recover approximately 4,805,000 ounces of silver and 179,000 ounces of gold over the 6.5 year life of the open pit phase of the Santa Elena Mine. A three year expansion plan is underway to double metals production at the Santa Elena Mine and exploration programs are rapidly advancing the definition of a large polymetallic deposit at the La Joya property in Durango State.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
The information provided in this news release is not intended to be a comprehensive review of all matters and developments concerning the Company. It should be read in conjunction with all other disclosure documents of the Company. The information contained herein is not a substitute for detailed investigation or analysis. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented.
J. Scott Drever, President
SILVERCREST MINES INC.
Contact:
SilverCrest Mines Inc.
Fred Cooper
(604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
(604) 694-1761 (FAX)
info@silvercrestmines.com
www.silvercrestmines.com
570 Granville Street, Suite 501
Vancouver, British Columbia V6C 3P1
Published at Investorideas.com Newswire
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SilverCrest Mines has compensated Investorideas.com for the distribution and publishing of this news release (annual news publication 9700) http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Tuesday, December 04, 2012

Stevia Stock Alert: Sunwin Stevia (OTCQB: SUWN) Expands Production Facility: Health Canada Approval and EU Approval Step Up Global Demand For Stevia

Point Roberts, WA - December 4, 2012 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors issues a news and trading alert for agriculture stevia stock, Sunwin Stevia International, Inc. (OTCQB:SUWN). Yesterday the Company announced the installation of new High tech production lines to expand stevia production capacity to 1,300 Metric Tons.

The stock moved to .$0.30 in Tuesday morning trading following the news, making recent new highs.
Stevia made headlines as Health Canada approved stevia November 30th as an additive to food and beverages. FoodIngrediantsfirst.com reported November 28 th referencing Sunwin's . (OTCQB:SUWN) marketing partner, WILD Flavors, “One year after the European Union granted approval for steviolglycosides to be marketed, WILD has noted positive interim results. The great-taste expert has worked with customers to create a number of stevia-sweetened products that have been market successes -- everything from beverages to candies.”
Sunwin began its expansion project in April 2012 in anticipation of an improvement in demand in the coming years as the use of stevia as a healthy low calorie sweetener continues to increase across the globe. Sunwin has begun trial production of its new lines and anticipates its added production capabilities to be fully operational in the first quarter of calendar 2013.
The completion of this high tech expansion of its production facilities brings Sunwin's total bulk stevia production capacity to 1,300 metric tons, including 500 metric tons of high grade stevioside products (Rabaudioside 60, 80, 95, 98, and 99) and 500 metric tons of steviosin which is a stevioside extract used in the pharmaceutical industry.
Investorideas.com Newswire Sunwin's new stevioside extraction line uses a state of the art crystallization process that substantially reduces the production time while increasing product yield. Sunwin believes this process will lead to a substantial reduction in overall processing costs as utilization rates increase. In addition, Sunwin's facilities are now capable of producing 500 metric tons of stevioside in granular and tablet forms on an annual basis. Demand for stevia in these forms has been increasing and management believes Sunwin is now poised to capitalize on this industry trend.
Article source: http://www.foodingredientsfirst.com/news/Wild-Sees-Positive-Interim-Results-One-Year-After-Stevia-Approval.html
About Sunwin Stevia International, Inc.
Sunwin Stevia International, Inc. engages in the areas of zero calorie, all natural sweeteners (Sunwin Stevia™ Extracts). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. For more info about Sunwin, please visit http://www.sunwininternational.com
About WILD Flavors GmbH,
WILD Flavors GmbH, based in Zug, Switzerland, is one of the world's leading privately-owned manufacturers of natural ingredients for the food and beverage industry. WILD Flavors provides specific flavors, colors, and ingredients as well as innovative and great tasting concepts through application expertise and technological advancements. For more information about WILD, please visit: www.wildflavors.com or www.wild.de.
Research more Agriculture and stevia stocks at Investorideas.com
http://www.investorideas.com/MSS/Arg_Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
More Sunwin info at Investorideas.com http://www.investorideas.com/CO/SUWN/
Download the IR App athttp://runningbullotc.com/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com is compensated by China Direct on behalf of SUWN, averaging four thousand two hundred per week for news publication, dissemination and profile on Invesotrideas.com , its affiliate news and email sites including ir app on Running Bull http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Energy Stock News; EFL Overseas Inc. (OTCBB: EFLO) Reports Acquisition of Additional Interest at Kotaneelee and Reserves and Resources Update

HOUSTON, TEXAS - December 4, 2012 (Investorideas.com energy newswire) EFL Overseas Inc. (OTCBB:EFLO) is pleased to announce the acquisition of additional working interests in the Kotaneelee gas property and the results of independent reserves and resources evaluations (NI-51-101 compliant).

ACQUISITION
Effective October 17, 2012, EFLO acquired a 30.664% interest in the Liard basin gas field and facilities located in the Kotaneelee Area, Yukon Territory, Canada (the "Assets") from Nahanni Energy Inc. and certain of its wholly owned subsidiaries ("Nahanni"). The Nahanni purchase follows EFLO's earlier acquisition of Devon Canada's interest (generally a working interest of 22.989%, with a working interest of 69.337% in one gas well) in the Assets. Upon closing the Nahanni purchase, EFLO became the largest interest holder in the Kotaneelee with a general interest of 53.65% and a working interest of 100% in one gas well.
"Our acquisition of the additional interest at Kotaneelee provides us with a controlling position in this exciting project", stated EFLO Chairman Henry Aldorf. "Increasing our working interest to approx. 54% allows us to drive forward development plans and offers our shareholders greater potential upside."
"With the closing of the Nahanni acquisition, we are focused on actively pursuing additional interests at Kotaneelee and the surrounding area," added EFLO Chief Executive Officer Keith Macdonald. "The larger asset base will be helpful as we evaluate our future market opportunities in the Pacific Rim, North America and the Yukon."
The Assets include 30,542 acres of land, a gas dehydration plant (capacity: 70 MMcf/d), one water disposal well (capacity: 6,000 bbls/d), one well temporarily shut-in for plant maintenance and two suspended gas wells, flarestack, storage tanks, airstrip, roads, gathering systems, geological data, equipment, and other transportation and camp infrastructure.
As consideration for the Assets, EFLO paid Nahanni US$132,600 in cash (representing closing consideration of Cdn$400,000 less certain pre-closing liabilities settled by EFLO), and 1,614,767 shares of one of its subsidiaries, which are exchangeable on a one-for-one basis for shares of EFLO's common stock (valued at Cdn$4,100,000; US$4,190,610). In addition, EFLO indemnified Nahanni against its portion of the abandonment, reclamation and environmental liabilities associated with the Assets. EFLO intends to undertake an active development and exploration program, which is expected to defer these potential liabilities into the future.
EFLO continues to pursue the acquisition of additional working interests in the Assets.
RESERVES
The following reports certain pro forma reserve information, after giving effect to both the Devon and Nahanni acquisitions, based on an independent assessments by AJM Deloitte ("AJM") of dated effective June 30, 2012 using forecast prices and costs (the "EFLO AJM Reserve Reports"). AJM prepared separate reports for the Devon and Nahanni acquired working interests. The numbers presented below reflect an aggregation of the two reports. The EFLO AJM Reserve Reports were prepared in accordance with definitions, standards and procedures contained in the Canadian Oil and Gas Evaluation Handbook ("COGE Handbook") and National Instrument 51-101 Standards of Disclosure for Oil and Gas Activities ("NI 51-101"). In addition reserve information required under NI 51-101 and effective for the EFLO's fiscal year ended August 31, 2012 will be included in NI 51-101 forms which will be filed in connection with EFLO's financial statements as at and for the year ended August 31, 2012. Such reserve information was filed on Sedar on November 29, 2012 and gives effect only to the Company's reserves resulting from the Devon acquisition, as the Nahanni acquisition occurred subsequent to August 31, 2012. The differences between Devon related reserves and net present values reported in the June 30 report and the August 31 report are not material.
Investorideas.com Newswire Gas prices for the report were based on delivery and sale at Station 2 in British Columbia. The EFLO AJM Reserve Reports base case forecast effective June 30, 2012 is as follows: 2012 - $2.00; 2013 - $2.95; 2014 - $3.55; 2015 - $3.95; 2016 - $4.35; 2017 - $4.80; 2018 - $5.35; 2019 - $5.80; 2020 - $6.50; and thereafter escalated at 2% per annum. Prices are in Canadian dollars per Mcf.
SUMMARY OF RESOURCES
The following reports certain pro forma resource information, based on an independent assessment by AJM dated effective June 30, 2012 using forecast prices and costs (the "EFLO AJM Resource Report"). The EFLO AJM Resource Report was prepared in accordance with definitions, standards and procedures contained in the COGE Handbook and NI 51-101.
The AJM Resource report evanuated the resources on EFLO acreage on gross terms and did not consider working interest. AJM evaluated the lands to assess the resource potential for the Middle Devonian Shales designated as Lower Black Shale (Muskwa/Evie), Middle Shale (Fort Simpson), and Upper Shale (Kotcho/Exshaw) as well as the potential for expansion of resource for the Nahanni on the producing East Flank. The results are summarized as follows, adjusted by management to reflect EFLO's 53.65% interest in the evaluated lands after giving effect to the Devon and Nahanni acquisitions.
Summary of Resources on EFL Overseas Lands (1)
Kotaneelee, Yukon Territory
Investorideas.com Newswire The following represents the total for the low, best and high cases as evaluated for the Shales.
Investorideas.com Newswire In addition, AJM has evaluated a Nahanni prospect on the West Flank.
Investorideas.com Newswire NOTICE REGARDING PRESENTATION OF THE COMPANY''S RESERVE AND CONTINGENT RESOURCE INFORMATION
The determination of reserves and resources involves the preparation of estimates that have an inherent degree of associated uncertainty. The estimation and classification of reserves and resources requires the application of professional judgment combined with geological and engineering knowledge to assess whether or not specific reserve or resource classification criteria have been satisfied. Knowledge of concepts including uncertainty and risk, probability, statistics and deterministic and probabilistic estimation methods is required to properly use and apply reserve and resource definitions.
Disclosure in this document of reserves and resources is presented in accordance with Canadian securities laws. The United States Securities and Exchange Commission (the "SEC") generally permits U.S. reporting oil and gas companies, in their filings with the SEC, to disclose only proved, probable and possible reserves and production, net of royalties and interests of others. The Company uses certain terms in this document, such as resources or contingent resources that the SEC's rules would prohibit a U.S. company from including in filings with the SEC. The SEC generally does not permit U.S. companies to disclose net present value of future net revenue from reserves based on forecast prices and costs. Canadian securities laws permit, among other things, the presentation of certain categories of resources and the disclosure of production on a gross basis before deducting royalties. Unless noted otherwise, all disclosures of reserves and resources in this document are made on a gross basis using forecast price and cost assumptions.
In this news release:
"gross" means:
(a) in relation to the Company's interest in production or reserves, its working interest share before deduction of royalties;
(b) in relation to wells, the total number of wells in which the Company has an interest; and
(c) in relation to properties, the total area of properties in which the Company has an interest.
"net" means:
(a) in relation to the Company's interest in production or reserves, its working interest share after deduction of royalty obligations;
(b) in relation to the Company's interest in wells, the number of wells obtained by aggregating the Company's working interest in each of its gross wells; and
(c) in relation to the Company's interest in a property, the total area of properties in which the Company has an interest multiplied by the working interest owned by the Company.
All evaluations of future revenue are after the deduction of royalties, development costs, production costs and well abandonment costs but before consideration of indirect costs such as administrative, overhead and other miscellaneous expenses.
Disclosure of Reserves
The reserves estimates and related estimates of net present values presented in this document were prepared to comply with Canadian reserves disclosure standards and reserves definitions as set out in NI 51-101 and the COGE Handbook prepared jointly by The Society of Petroleum Evaluation Engineers (Calgary Chapter) and the Canadian Institute of Mining, Metallurgy & Petroleum (Petroleum Society).
Reserves are estimated remaining quantities of oil and natural gas and related substances anticipated to be recoverable from known accumulations, from a given date forward, based on:
  • analysis of drilling, geological, geophysical and engineering data;
  • the use of established technology; and
  • specified economic conditions, which are generally accepted as being reasonable.
Reserves are classified according to the degree of certainty associated with the estimates:
  • Proved reserves are those reserves that can be estimated with a high degree of certainty to be recoverable. It is likely that the actual remaining quantities recovered will exceed the estimated proved reserves;
  • Probable reserves are those additional reserves that are less certain to be recovered than proved reserves. It is equally likely that the actual remaining quantities recovered will be greater or less than the sum of the estimated proved plus probable reserves; and
  • Possible reserves are those additional reserves that are less certain to be recovered than probable reserves. It is unlikely that the actual remaining quantities recovered will exceed the sum of the estimated proved plus probable plus possible reserves.
Each of the reserves categories (proved, probable and possible) may be divided into developed and undeveloped categories:
  • Developed reserves are those reserves that are expected to be recovered from existing wells and installed facilities or, if facilities have not been installed, that would involve a low expenditure (for example, when compared to the cost of drilling a well) to put the reserves on production. The developed category may be subdivided into producing and non-producing.
  • Developed producing reserves are those reserves that are expected to be recovered from completion intervals open at the time of the estimate. These reserves may be currently producing or, if shut-in, they must have previously been on production, and the date of resumption of production must be known with reasonable certainty.
  • Developed non-producing reserves are those reserves that either have not been on production, or have previously been on production, but are shut-in, and the date of resumption of production is unknown.
  • Undeveloped reserves are those reserves expected to be recovered from known accumulations where a significant expenditure (for example, when compared to the cost of drilling a well) is required to render them capable of production. They must fully meet the requirements of the reserves classification (proved, probable, possible) to which they are assigned.
In multi-well pools it may be appropriate to allocate total pool reserves between the developed and undeveloped categories or to subdivide the developed reserves for the pool between developed producing and developed non-producing. This allocation should be based on the estimator's assessment as to the reserves that will be recovered from specific wells, facilities and completion intervals in the pool and their respective development and production status.
The qualitative certainty levels referred to in the definitions above are applicable to individual reserves entities (which refers to the lowest level at which reserves calculations are performed) and to reported reserves (which refers to the highest level or the sum of individual entity estimates for which reserves estimates are presented). Reported reserves should target the following levels of certainty under a specific set of economic conditions:
  • at least a 90 percent probability that the quantities actually recovered will equal or exceed the estimated proved reserves;
  • at least a 50 percent probability that the quantities actually recovered will equal or exceed the sum of the estimated proved plus probable reserves; and
  • at least a 10 percent probability that the quantities actually recovered will equal or exceed the sum of the estimated proved plus probable plus possible reserves.
Additional clarification for the classification of reserves and the certainty levels associated with reserves estimates is provided in the COGE Handbook.
Disclosure of Resources
In this news release, the Company also refers to estimates of "contingent resources". These estimates represent the best estimate of the contingent resources attributed to the Company's interest, are not classified or recognized as reserves, and are in addition to the Company's disclosed reserve volumes.
Contingent resources are those quantities of petroleum estimated, as of a given date, to be potentially recoverable from known accumulations using established technology or technology under development, but which are not currently considered to be commercially recoverable due to one or more contingencies. Contingencies may include factors such as economic, legal, environmental, political, and regulatory matters, or a lack of markets. It is also appropriate to classify as contingent resources the estimated discovered recoverable quantities associated with a project in the early evaluation stage. There is no certainty that it will be commercially viable to produce any portion of the contingent resources and the estimated future net revenues do not necessarily represent the fair market value of such contingent resources.
The Company's resources classified as contingent resources, rather than as reserves, are so classified pending the need for further facility design, preparation of firm development plans and regulatory applications (including associated reservoir studies and delineation drilling) and corporate approvals to proceed with development.
When evaluating contingent resources, the following mutually exclusive categories are recommended in the COGE Handbook:
  • Low Estimate: This is considered to be a conservative estimate of the quantity that will actually be recovered. It is likely that the actual remaining quantities recovered will exceed the low estimate. If probabilistic methods are used, there should be at least 90 percent probability that the quantities actually recovered will equal or exceed the low estimate.
  • Best Estimate: This is considered to be the best estimate of the quantity that will actually be recovered. It is equally likely that the actual remaining quantities recovered will be greater or less than the best estimate. If probabilistic methods are used, there should be at least a 50 percent probability that the quantity actually recovered will equal or exceed the best estimate.
  • High Estimate: This is considered to be an optimistic estimate of the quantity that will actually be recovered. It is unlikely that the actual remaining quantities recovered will exceed the high estimate. If probabilistic methods are used, there should be at least a 10 percent probability that the quantities actually recovered will equal or exceed the high estimate.
FORWARD-LOOKING STATEMENTS
This news release includes forward-looking statements, including but not limited to estimates of reserves and resources and the present value of revenues associated with such reserves and resources. Statements in this news release relating to reserves and resources involve the implied assessment, based on certain estimates and assumptions, that the described reserves and resources, as the case may be, exist in the quantities predicted or estimated, and can be profitably produced in the future. There is no assurance that the forecast price and cost assumptions contained in the AJM reports will be realized and variances could be material. Other assumptions and qualifications relating to project schedules, costs and other matters are inherent in these estimates.
In addition, all statements other than statements of historical facts, included in this news release that address activities, events, or developments that the Company believes or anticipates will or may occur in the future are forward-looking statements, including but not limited to the Company's intent to pursue the acquisition of additional interest in the Kotaneelee property, the Company's planned exploration activities and the existence of potential opportunities in the Pacific Rim, North America and the Yukon. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to acquire and develop specific projects and reach commercially acceptable terms with counterparties, the ability to secure government and other third party approval, potential third party claims, the ability to fund operations, and other factors over which the Company has little or no control. The Company does not intend to update publicly any forward-looking statements, except as may be required by law. There can be no assurance that EFLO will be successful in completing the acquisition of additional interest(s) in the Kotaneelee properties or executing its planned exploration and development activities.
The contents of this news release should be considered in conjunction with the warnings and cautionary statement contained in the Company's public filings, which are accessible on SEDAR at www.sedar.com.
Definitions
In this news release: (i) Mcf means thousand cubic feet; (ii) Mcf/d means thousand cubic feet per day; (iii) MMcf means million cubic feet; (iv) MMcf/d means million cubic feet per day; (v) bbls means barrels; (vi) Mbbls means thousand barrels; (vii) MMbbls means million barrels; (viii) bbls/d means barrels per day; (ix) Bcf means billion cubic feet; (x) Mboe means thousand barrels of oil equivalent; (xi) MMboe means million barrels of oil equivalent; (xii) boe means barrels of oil equivalent; and (xiii) boe/d means barrels of oil equivalent per day.
Boe means barrel of oil equivalent on the basis of 1 boe to 6,000 cubic feet of natural gas. References to boe may be misleading, particularly if used in isolation. A boe conversion ratio of 1 boe for 6,000 cubic feet to natural gas is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead.
Contact:
EFL Overseas Inc.
Keith Macdonald
1 (403) 246-8443

Medical Device Stock Trading Alert: Aethlon Medical (OTCBB: AEMD) Closes up 11.9% on News

Point Roberts WA - December 4, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the initiation of a compassionate-use clinical program to treat individuals infected with Hepatitis C virus (HCV). The compassionate-use program, which has been approved by the Institutional Review Board at the Medanta Medicity Institute (Medicity), will provide individuals who previously failed or subsequently relapsed standard-of-care drug regimens with treatment access to the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of HCV from the entire circulatory system to improve benefit, dosing, duration and tolerability of drug therapies.
Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors including biotech and medical technology stocks issues a trading alert for Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. The stock closed up Monday 11.9% on over 720,000 shares volume following news of the initiation of a compassionate-use clinical program to treat individuals infected with Hepatitis C virus (HCV).
Investorideas.com Newswire Full news: http://www.investorideas.com/CO/AEMD/news/2012/12031.asp
About Aethlon Medical

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with DARPA that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Published at Investorideas.com Newswire
More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/
Disclaimer: Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release. Aethlon Medical, Inc. is currently an annual news release client at Investorideas.com and compensates Investorideas.com $2425 quarterly to publish and distribute news with Investorideas and its syndication partners
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source Investorideas.com 800 665 0411

Colombian Coal Stock Alert: VSUS Technologies (OTCQB:VSUT) Announces Retirement of Debt and Board Resignations

BOGOTA - December 4, 2012 (Investorideas.com Mining stocks newswire) VSUS Technologies Inc. (OTCQB: VSUT) ("VSUS" or the "Company") announced today it has retired significant company debt. The Company is also announcing the resignation of two officers.

Kyle Gotshalk and Cherish Adams have resigned as officers of VSUS Technologies Inc. Their resignations were part of a debt settlement agreement and not due to any disagreements or conflicts with the company or its management. VSUS Technologies has entered into a debt settlement agreement with Ararat LLC that will reduce the company's liabilities by approximately $ 500,000. The Company has also paid in full two convertible promissory notes with Asher Enterprises totaling approximately $ 80,000 in principal, interest, and premium. The Company still has a third note with Asher it intends to pay in full next month. The retirement of this debt not only significantly reduces company liabilities but also the expense associated with carrying that debt.
The two resigning directors have returned approximately 7.75 Million shares to the company which currently has 75,938,476 shares outstanding. According to our transfer agent, as of December 3, 2012, there are 20,713,000 shares with CEDE & Co., nominee for the Depository Trust Corporation (DTC).
"We have made considerable progress with our studies and land surveys in Colombia; we expect to submit both our environmental impact assessment and works program to the proper agencies in the coming weeks. We will begin to interview operators and execute land purchase agreements in the next quarter," commented John Campo, President.
VSUS Technologies is building a strong team of geologists and engineers on the ground in Colombia and will be adding new board members at the appropriate time. The company will be rebuilding their website in 10 languages to engage social media and showcase their projects and studies to interested investors around the world. The company will establish a new corporate identity committed to keeping investors more informed going forward.
Get News Alerts & Updates for VSUS Technologies, Inc. delivered directly to your Mobile Phone. Text VSUT to 54545 or visit http://vsus.mobi (News alerts are free; however standard message & data rates may apply. Check with your carrier for more details.)
About VSUS Technologies Inc.
VSUS Technologies is a growing company that is acquiring coal concessions in Colombia in order to satisfy the world market demand for coal. Once a concession is acquired and the necessary financing is obtained, the Company will begin all the required environmental and geological studies to get them into production as efficiently as possible. The Company plans to have three revenue producing business units in Colombia: coal mining, coking oven facilities, and docks and river transportation along the Magdalena River. For more information on our company visit our website at www.vsustechnologies.com
Forward Looking Statements
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include financing, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations. VSUS Technologies, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Company Contact:
VSUS Technologies Inc.
Mr. John Campo
President
(1)-410-236-8200 USA
(57) 318-657-0918 Colombia
jcampo@vsustechnologies.com
VSUS Colombia
Cra. 16 # 79-31 Suite 703a
Bogota, Colombia
www.vsustechnologies.com
Published at Investorideas.com newswire
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Investorideas.com was compensated five hundred for the publishing of this release . http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Mining Stock News: SilverCrest (TSX.V: SVL) (NYSE MKT: SVLC) Updates Santa Elena Resource Infill and Expansion Drilling

VANCOUVER, BRITISH COLUMBIA - December 4, 2012 (Investorideas.com Mining Stocks Newswire) SilverCrest Mines Inc. (TSX.V:SVL) ( NYSE MKT: SVLC) (CW5.F) (the "Company") is pleased to announce results of further drilling at the Santa Elena Mine in Sonora, Mexico. Seventy nine holes of a planned 100 holes have been completed to re-categorize Indicated and Inferred Resources to Probable Reserves and expand current underground Resources (see attached Figures - http://media3.marketwire.com/docs/svl1204-F1-2.pdf). To date, this drill program has been successful and will assist with resource confirmation and conversion which will be included in the upcoming Pre-Feasibility Study for the Santa Elena Expansion Project.
Assay values in this series of holes range from 0.22 gpt to 4.92 gpt gold and 28.0 to 277.4 gpt silver. Mineralized intervals range from 1.0 metres to 38.9 metres. All mineralized drill intercepts are near true thicknesses. The most significant intercepts are 30.7 metres grading 1.61 gpt Au and 169.6 gpt Ag (Hole SE-12-54) and 16 metres grading 2.15 gpt Au and 166.9 gpt Ag (Hole SERC-12-36). The most significant assay results in this series of holes are shown in the following table;
Investorideas.com Newswire * Silver Equivalency based on a Ag:Au ratio of 50:1. All numbers are uncut and rounded.
** The SERC holes were drilled to intercept the Main Mineralized Zone utilizing reverse circulation drilling at the top of the hole and core through the mineralized interval.
All sample analyses were completed by ALS Chemex in Hermosillo, Mexico and North Vancouver, BC.

Assays are pending for Holes SE-12-49 and SE-12-53, in the above sequence. "GT" numbered holes are geotechnical holes that are being used for underground mine design for the Expansion Pre-Feasibility Study. Holes SERC-12-23, 25 and 26 had significant downhole deviations and were subsequently abandoned.
The Santa Elena deposit (Main Mineralized Zone) is open along strike and depth. Core holes SE-12-72 and SE-12-73 have been completed as part of a 15 hole program to test for the possible expansion of resources along strike to the east and to depth. Mineralized intercepts in these two holes are 5 to 10 metres wide with banded quartz and argentite mixed with breccia and disseminated argentite. These intercepts are approximately 100 to 150 metres beyond the boundary of current resource estimates. Approximately 13 additional holes are planned in this area as steps outs along strike and to depth. The Company is awaiting assay results for holes 72 and 73 to determine the extent of expansion potential.
Seventy nine holes totaling 25,512 metres of drilling have been completed to date in the underground resource conversion to reserves and resource expansion program. Results for the next series of holes will be released once compilation of results is complete. Three drills are currently on site to complete the program by the end of 2012. Revised Santa Elena Resources and Reserves, along with the results of Pre-Feasibility Study for the Expansion Plan are expected in Q1 2013.
The Qualified Person under National Instrument (NI 43-101) Standards of Disclosure for Mineral Projects for this News Release is N. Eric Fier, CPG, P.Eng, and Chief Operating Officer for SilverCrest Mines Inc., who has reviewed and approved its contents.
SilverCrest Mines Inc. (TSX-V: SVL; NYSE MKT: SVLC) is a Canadian precious metals producer headquartered in Vancouver, BC. SilverCrest's flagship property is the 100%-owned Santa Elena Mine, located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, Mexico. The mine is a high-grade, epithermal gold and silver producer, with an estimated life of mine cash cost of US$8 per ounce of silver equivalent (55:1 Ag:Au). SilverCrest anticipates that the 2,500 tonnes per day facility should recover approximately 4,805,000 ounces of silver and 179,000 ounces of gold over the 6.5 year life of the open pit phase of the Santa Elena Mine. A three year expansion plan is underway to double metals production at the Santa Elena Mine and exploration programs are rapidly advancing the definition of a large polymetallic deposit at the La Joya property in Durango State.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
The information provided in this news release is not intended to be a comprehensive review of all matters and developments concerning the Company. It should be read in conjunction with all other disclosure documents of the Company. The information contained herein is not a substitute for detailed investigation or analysis. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented.
J. Scott Drever, President
SILVERCREST MINES INC.
Contact:
SilverCrest Mines Inc.
Fred Cooper
(604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
(604) 694-1761 (FAX)
info@silvercrestmines.com
www.silvercrestmines.com
570 Granville Street, Suite 501
Vancouver, British Columbia V6C 3P1
Published at Investorideas.com Newswire
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SilverCrest Mines has compensated Investorideas.com for the distribution and publishing of this news release (annual news publication 9700) http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Medical Technology Stock Research Alert for Decision Diagnostics (OTCBB: DECN)

Point Roberts, WA - December 4, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research for independent investors publishes CFA commentary on Decision Diagnostics Corp. (OTCBB: DECN), by Patrick J. Murphy of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks.

Decision Diagnostics Corp. (OTCBB: DECN)
Patrick J. Murphy
Decision Diagnostics Corp. is developing products that offer unique solutions in medical care. The Shasta GenStrip® is an at home diagnostic for testing blood glucose designed to run on the Johnson & Johnson's (NYSE: JNJ) LifeScan LifeFirst™ OneTouch® family of meters, which are used by over 5 million people in the U.S. alone and for which JNJ estimates 97% of patients, including those with Medicare, are insured.
Of the products developed by DECN, the Company's Shasta GenStrip® in particular has significant potential for helping the rapidly growing diabetic population. DECN reports that the application for the Shasta GenStrip® was submitted to the FDA in December of 2010, and although the approval process typically now takes in excess of two years, DECN is now responding to a short series of follow up questions from the FDA, subsequent to recent meetings.
Select Stock Trading Data
Recent Stock Price: $0.17
Shares Outstanding: 11.48 million
Float 8.4 million
Recent Market Cap: $1.95 million
52 Week Range: $0.05 - $0.65
Exchange: OTCBB
Ticker: DECN
URL: http://www.decisiondiagnostics.com/
Data sourced from Yahoo! Finance; otcbb.com; Company filings
In terms of the overall market opportunity, a report from Research and Markets estimates that the global blood glucose monitoring market was estimated to be worth $8.9 billion in 2010 and is expected to grow 4.5% annually to reach $12.2 billion, with blood glucose test strips representing nearly 90% of the market at $10.9 billion. The report also cites International Diabetes Federation that diabetes affected 366 million people in 2011, or 8.3% of the global population, and that this is projected to increase to 9.9% of the population by 2030.
Trends in the U.S. serve to illustrate what is driving the increase in diabetes - the rise in obesity. According to the American Diabetes Association , approximately 26 million people in the U.S. have diabetes, representing 8.3% of the population, with 1.9 million new cases in 2010. The high prevalence of diabetes is not surprising in light of the data from the Centers for Disease Control (CDC) , which reports that during the past 20 years, there has been a dramatic increase in obesity in the United States and rates remain high at nearly 36% of U.S. adults and approximately 17% of children and adolescents aged 2—19. Similarly, metabolic syndrome affects nearly 50 million people in the U.S. Alone: As addressed by the National Institute of Health:
"Metabolic syndrome is a name for a group of risk factors that occur together and increase the risk for coronary artery disease, stroke, and type 2 diabetes. Metabolic syndrome is becoming more and more common in the United States. Researchers are not sure whether the syndrome is due to one single cause, but all of the risks for the syndrome are related to obesity.”
Unlike many competing product offerings, Genstrip employs a razor blade only model, a diagnostic test strip, and DECN has stated that the product is likely to cost less than 50% of the branded product without sacrificing quality. As an illustration of the potential appetite for the Genstrip product, DECN's 10-Q notes that the Company was approached by the largest retailer in the world, recently revealed to be Wal-Mart by DECN President and CFO Keith Berman, regarding the sale of Genstrip at its 5,000+ stores globally. DECN reports that a contract was negotiated in September 2010 and subsequently renegotiated and renewed in April 2011. However, while conducting market research during this time and seeking pre-orders, DECN reports that initial market interest was greater than the product capacity of the Company's contract manufacturer, and the Company ended the pre-order initiative while remaining confident there is a very large opportunity for Genstrip in a market dominated by four large pharmaceutical manufacturers which DECN reports sell similar products at similar pricing.
It seems reasonable to speculate increasing prosperity around the world is creating greater disposable income for increasing segments of the population, with increasing leisure time and presumably less manual labor. Whatever the cause or causes may be, the trend towards an increase in obesity and a resulting increase in the diabetes population seems clear, as does the potential opportunity for products that serve that market. Although FDA approval is of course not a certainty, DECN seems to have developed a product with significant potential if approval is obtained.
DECN also has developed a line of medical IT products for the rapidly expanding EMR/HER market. Unlike other medical information systems using standard computer terminals, Decision Diagnostics Corp. uses smart phones, which allow physicians to carry, access and update their patients' histories, medication data, and best care guidelines - all at the point of care. Decision Diagnostics Corp. is a provider of prescription drugs, home testing products for the chronically ill, a fulfillment provider of direct to patient diabetes programs, and a developer of cutting edge cell phone centric e-health products and technologies.
Patrick Murphy Bio:
Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks. Mr. Murphy has nearly 20 years of capital markets experience providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's. In addition to his work with Murphy Analytics, Mr. Murphy also serves as a consultant to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of the University of Notre Dame (1991), with an undergraduate degree in Economics, and earned a Masters Degree in Finance from St. Louis University in 1997. Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St. Louis.
Patrick Murphy Disclaimer:
Readers are advised that the above article is solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. The views expressed herein are based upon the author's analysis of the issuer's public disclosures, and assumes both their accuracy and completeness. The opinions and statements included herein are based on sources (including the companies discussed and public sources) believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. The author has not independently verified the information contained herein. This information is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. You should review a complete information package on all companies, which should include, but not be limited to, the Company's annual report, quarterly reports, press releases and all regulatory filings. The foregoing discussion contains statements which are based on current expectations, estimates and projections, and differences from such expectations, estimates and projections can be expected. The author, Patrick Murphy, was compensated $500 by InvestorIdeas.com for writing this article. Murphy does not own shares of any of the companies mentioned in this article. Mr. Murphy's research firm, Murphy Analytics, may be engaged for the provision of a research report on the Company in the future.
Decision Diagnostics Company websitehttp://www.decisiondiagnostics.com/
DECN SEC quarterly file
http://biz.yahoo.com/e/120820/decn10-q.html
More info on DECN at Investorideas.com http://www.investorideas.com/CO/DECN/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: Investorideas.com has been compensated one hundred fifty thousand shares for news and content publication and distribution for 45 days
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
http://www.lifescan.com/about-us
http://www.onetouch.com/onetouch-diabetes-testing-supplies
http://www.pharmpro.com/News/2011/05/Animas-and-LifeScan-Strengthen-Strategic-Focus-to-Better-Serve-People-Living-with-Diabetes/
http://www.investorideas.com/CO/DECN/news/2012/11211.asp
http://www.businesswire.com/news/home/20120111006216/en/Research-Markets-Blood-Glucose-Test-Strips-Market
http://www.diabetes.org/diabetes-basics/diabetes-statistics/?loc=DropDownDB-stats
http://www.cdc.gov/obesity/data/facts.html
http://www.ncbi.nlm.nih.gov/pubmed/17893688
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004546/
http://www.investorideas.com/CO/DECN/news/2012/11281.asp

Monday, December 03, 2012

NASDAQ Top Movers; (CYCC), (CALI), (CZR), (TRNS)

New York, New York - December 3, 2012 (www.investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors reports on the top percentage gainers on the NASDAQ for December 3rd, 2012.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is the top morning mover trading at $ 5.85, and gaining $0.68, or 13.20% on a volume of 275,005 shares.
China Auto Logistics Inc, (NASDAQ: CALI) is trading up at $4.84, gaining $0.52, or 11.99% on a volume of 515,088 shares. China Auto Logistics Inc, reported earlier today that it has been notified by the Listing Qualifications department of The Nasdaq Stock Market that the Company has regained compliance with the $5 million minimum market value of publicly held shares requirement of the Nasdaq Global Market.
Caesars Entertainment Corporation, (NASDAQ: CZR) gained from $ 6.80 by $0.70 or 11.48% on a volume of 542,433 shares.
Transcat Inc. (NASDAQ: TRNS), trading at $7.96 gained $0.81, or 11.33% on a light volume of 22,274 shares. Transcat announced just last Thursday to have invested in an additional calibration system to expand its pressure calibration capabilities and enhance customer response times. The addition gives Transcat four distinct pressure systems that can be utilized for quality pressure calibrations, improving the Company’s capabilities.
About NASDAQ
http://www.nasdaq.com/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 13 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces Initiation of Compassionate-Use Program to Treat Hepatitis C Virus (HCV)

SAN DIEGO - December 3, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the initiation of a compassionate-use clinical program to treat individuals infected with Hepatitis C virus (HCV). The compassionate-use program, which has been approved by the Institutional Review Board at the Medanta Medicity Institute (Medicity), will provide individuals who previously failed or subsequently relapsed standard-of-care drug regimens with treatment access to the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of HCV from the entire circulatory system to improve benefit, dosing, duration and tolerability of drug therapies.
Investorideas.com Newswire

The Medicity is a $360 million multi-specialty medical institute established to be a premier center for medical tourism in India. Additional details about the Medicity can be found online at www.medanta.org.
It is estimated that approximately 170 million people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is a leading cause of liver transplantation. The opportunity to address infected individuals who fail or subsequently relapse drug therapy is significant as retreatment prognosis with drug therapy alone is often poor. Under the compassionate-use program, the Medicity is offering Hemopurifier® therapy to HCV-infected individuals that reside in India or travel from other regions and meet the inclusion/exclusion criteria that have been established for participation.
"We are grateful to the Medicity for providing us the opportunity to improve Hepatitis C treatment outcomes," stated Aethlon Chairman and CEO, Jim Joyce. "While we plan to be cautious in our initial ramp-up, we do look forward to augmenting our established contract revenue stream with Hemopurifier® product sales."
The Treatment Protocol
The Medicity is offering compassionate-use access to Hemopurifier® therapy on a minimum three-day treatment regimen with the option for patients to extend treatment to a maximum period of seven consecutive days. During each treatment day, Hemopurifier® therapy is administered for a duration up to six-hours. In HCV, the goal of therapy is to accelerate the early viral kinetic response to standard-of-care drug therapy without adding drug toxicity or interaction risks. More specifically, Hemopurifier® therapy targets to increase immediate and rapid virologic response rates, which correlate with high clinical cure rates.
Medicity is offering the three-day treatment regimen at $7,235.00 (USD), which includes Hemopurifier® therapy, physician and support fees, hospital lodging, catheter and other consumables. The cost for each treatment day beyond the minimum three-day regimen is $2,295.00. Pre-treatment consult and post treatment monitoring is charged at $200/day and includes transportation to and from hotel.
The Medicity has established the following inclusion and exclusion criteria for candidate patient consideration:
Inclusion Criteria
  • Males or females 18 years of age and older testing positive for any HCV genotype
  • Patients who relapsed after completing a previous course of standard-of-care drug therapy
  • Null responders or patients who previously were unable to achieve > 2 log viral load reduction at month three of standard of care drug therapy
  • Candidate patients must be willing to submit to temporary vascular access catheterization
  • Ability to tolerate blood volume losses of up to 150 ml per week
  • Stable clinical condition, including stable hematocrit
  • Patients on ACE inhibitors must suspend ACE inhibitor administration for a minimum of six days prior to initiating therapy.
  • Karnofsky score ≥ 60
  • A more detailed list of inclusion criteria, including blood chemistry requirements will be provided to candidate patients who meet the above criteria
  • The subject must be informed of the investigational nature of this study and written informed consent obtained prior to enrollment in this study
Exclusion Criteria
  • Clinically significant infection, other than HCV, defined as any acute viral, bacterial, or fungal infection, which requires specific therapy (Anti-infectious therapy must have been completed at least 14-days before entry into study).
  • Co -infections with Hepatitis B virus and Human immunodeficiency virus ( HIV )
  • Received any investigational agent(s) within 28-days of entry into study
  • Any known pre-existing medical condition that could interfere with the subject's participation in the protocol, including serious psychiatric disorders, CNS trauma or active seizure disorders requiring medication, poorly controlled diabetes mellitus, significant cardiovascular dysfunction within the past 6 months (e.g., angina, congestive heart failure, recent myocardial infarction, severe hypotension, or significant arrhythmia)
  • Subjects with ECG showing clinically significant abnormalities
  • Need for frequent blood transfusions.
  • Recent History of bleeding or bleeding disorders requiring the restriction in use of anticoagulants during study treatments.
  • Active immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], rheumatoid arthritis, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, autoimmune or inherited hemolytic anemia, scleroderma, severe psoriasis).
  • Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids or other immunoregulatory medications
  • Substance abuse, such as alcohol (~80 gm/day), IV drugs, and inhaled drugs (If the subject has a history of substance abuse, to be considered for inclusion into the protocol, the subject must have abstained from using the abused substance for at least 2 months. Subjects receiving methadone within the past year are also excluded.)
  • Any cancer requiring systemic chemotherapy
  • Any other condition that, in the opinion of the Principal Investigators, would make the subject unsuitable for enrollment, or could interfere with the subject participating in and completing the protocol
Individuals interested in the study are encouraged to contact:
Dr Puneet Sodhi
Mail ID: puneet.sodhi@Medanta.org
Contact No.: +91-9910002681
Jitendra Kumar Gupta
Mail ID: jitendra@qualtran.com
Contact No.: +91-9313365371
Information requests can also be sent directly to Aethlon Medical at: info@aethlonmedical.com
Current HCV Studies
Aethlon has previously reported data from a clinical program at the Medicity that is evaluating the capability of the Aethlon Hemopurifier® to accelerate HCV RNA depletion at the outset of standard of care peginterferon+ribavirin (PR) therapy. In this study, HCV-infected individuals are enrolled to receive up to three, six-hour Hemopurifier® treatments during the first three days of PR drug therapy. Aethlon recently reported that two HCV-infected patients who received Hemopurifier® therapy in combination with PR drug therapy achieved undetectable viral load at day-7, which is rarely reported in drug therapy alone.
The primary clinical endpoint of this study protocol has been to increase the incidence of rapid virologic response (RVR), defined as undetectable HCV RNA at day 30 of therapy. RVR represents the clinical endpoint that best predicts treatment cure, otherwise known as sustained virologic response (SVR), defined as undetectable HCV RNA 24-weeks after the completion of PR drug therapy. As a point of reference, the landmark IDEAL Study of 3,070 HCV genotype-1 patients documented that only10.35% (n=318/3070) of PR treated patients achieved a RVR. However, patients that achieved a RVR had SVR rates of 86.2% (n=274/318) versus SVR rates of 32.5% (n=897/2752) in non-RVR patients. While the incidence of undetectable HCV RNA at day-7 is not reported in the IDEAL study, the study did reveal that just 4.3% (n=131/3070) of patients achieved undetectable HCV RNA at day-14, which equated to a 91% (n=118/131) SVR rate.
To date, Aethlon has reported that Hemopurifier® therapy has been well tolerated and without device-related adverse events in the first ten treated patients. Of theseten patients, seven patients were infected with HCV genotype-1; two patients were infected with HCV genotype-3; and one patient was infected with HCV genotype-5. Aethlon previously reported undetectable HCV RNA in eight of the 10 treated patients. Of the two patients reported to have detectable HCV RNA, one had discontinued PR therapy as a result of a diabetes related condition. HCV RNA is undetectable in all patients (n=4) that have been monitored for 48 weeks since receiving Hemopurifier® therapy.Among the 10 treated patients, Aethlon reported that six genotype-1 patients received the three treatment Hemopurifier® protocol, which resulted in four (67%) patients achieving a RVR. The IDEAL study predicts it would normally require approximately 40 PR treated patients to achieve 4 RVR outcomes. Both patients who achieved undetectable HCV RNA at day-7 also achieved a RVR. Beyond the high likelihood of a SVR, genotype-1 patients that achieve a RVR also have the opportunity to reduce the duration of PR drug therapy from 48 weeks to 24 weeks.
Aethlon expects to report updated results, including new patient data from this study in the near future. The Company also disclosed it is presently incorporating new patient data within investigational device exemption (IDE) that is expected to be submitted to FDA by year-end in an effort to gain approval to initiate HCV clinical programs in the United States.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with DARPA that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs